26.70 +0.05 (0.17%)
After hours: 4:11PM EST
|Bid||25.00 x 800|
|Ask||28.50 x 2900|
|Day's Range||26.40 - 27.59|
|52 Week Range||22.02 - 42.67|
|Beta (3Y Monthly)||1.42|
|PE Ratio (TTM)||220.25|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Today we'll evaluate National Vision Holdings, Inc. (NASDAQ:EYE) to determine whether it could have potential as an...
National Vision (EYE) delivered earnings and revenue surprises of 50.00% and 1.45%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
National Vision (EYE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is National Vision Holdings, Inc. (NASDAQ:EYE) a good bet right now? We like to analyze hedge fund sentiment before conducting days of in-depth research. We do so because hedge funds and other elite investors have numerous Ivy League graduates, expert network advisers, and supply chain tipsters working or consulting for them. There is not a […]
It's easy to match the overall market return by buying an index fund. While individual stocks can be big winners...
National Vision Holdings has been the fastest-growing U.S. optical chain for a decade, with just about every broker calling the stock a Buy. Shares have fallen by half over the past year, however, and bearish investors are taking aim.
In this article we are going to estimate the intrinsic value of National Vision Holdings, Inc. (NASDAQ:EYE) by taking...
We consider this corporate deal in Brazil to be a strategic fit for GNC Holdings (GNC), which currently pulls out all the stops to fortify its global footprint.
National Vision (EYE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Genomic Health (GHDX) is on course to realize its impending merger with cancer diagnostics major Exact Sciences, which will integrate brands like Cologuard and OncotypeDX.
The U.S. stock market has been on shaky ground in recent weeks after a yield curve inversion and a new round of tariff threats between the U.S. and China has investors spooked about the possibility of ...
Baxter (BAX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
One of the best investments we can make is in our own knowledge and skill set. With that in mind, this article will...
National Vision (EYE) delivered earnings and revenue surprises of -4.76% and 1.99%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?